Pfenex Inc. (PFNX): Price and Financial Metrics
GET POWR RATINGS... FREE!
PFNX Stock Price Chart Interactive Chart >
PFNX Price/Volume Stats
|Current price||$12.75||52-week high||$14.00|
|Prev. close||$12.76||52-week low||$5.26|
|Day high||$12.94||Avg. volume||503,865|
|50-day MA||$11.26||Dividend yield||N/A|
|200-day MA||$9.82||Market Cap||437.29M|
Pfenex Inc. (PFNX) Company Bio
Pfenex is a clinical-stage biotechnology company engaged in the development of biosimilar therapeutics and high-value and difficult to manufacture proteins. Pfenex was founded in 2009 and was based in San Diego, California.
Most Popular Stories View All
PFNX Latest News Stream
|Loading, please wait...|
PFNX Latest Social Stream
View Full PFNX Social Stream
Latest PFNX News From Around the Web
Below are the latest news stories about Pfenex Inc that investors may wish to consider to help them evaluate PFNX as an investment opportunity.
SAN DIEGO--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced today that its wholly-owned subsidiary, Pelican Acquisition Sub, Inc. (the “Purchaser”), is commencing a tender offer to purchase all outstanding shares of common stock of Pfenex, Inc. (NYSE American: PFNX) at an offer price of $12.00 per share in cash, plus one non-transferable contractual contingent value right per share representing the right to receive a contingent payment of $2.00 in cash, if a certain
PFENEX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Pfenex Inc. - PFNX
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Pfenex Inc. (NYSE: PFNX) to Ligand Pharmaceuticals Incorporated (NasdaqGM: LGND). Under the terms of the proposed transaction, shareholders of Pfenex will receive $12.00 in cash, and a one-time contingent value right of $2.00 in the event a predefined regulatory milestone is achieved by December 31, 2021, for
Gainers: Pfenex (PFNX) +67%. Eyenovia (EYEN) +44%. ProPhase Labs (PRPH) +38%. Trevi Therapeutics (TRVI) +20%. Pieris Pharmaceuticals (PIRS) +18%.Losers: Fulcrum Therapeutics (FULC) -44%. Mesoblast (MESO) -37%. Fennec Pharmaceuticals (FENC) -35%. Genesis Healthcare (GEN) -28%. PDS Biotechnology (PDSB) -24%....
Ligand Pharmaceuticals is set to acquire Pfenex in the fourth quarter of 2020. The two San Diego biotechs rely on developing early-stage tools and licensing them out to other companies.
NEW YORK, Aug. 11, 2020 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Pfenex, Inc. ("PFNX" or the "Company") (NYSE American: PFNX) in connection with the proposed acquisition of the Company by…
PFNX Price Returns